Drug intelligence / Profile preview

CT111

Development stage: Unknown
Lead developer: Chantibody Therapeutics
Modality: Trispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics
Administration: Intravenous

Overview

**CT111** is a novel trispecific single-domain antibody developed by Chantibody Therapeutics that simultaneously targets **PD-1**, **CTLA-4**, and **VEGF**. It functions as a **PD-1 inhibitor**, **CTLA-4 inhibitor**, and **VEGF inhibitor**, synergistically blocking immune checkpoints on exhausted T cells while inhibiting angiogenesis to promote cooperative antitumor effects. Currently in early clinical development, with preclinical data demonstrating enhanced T-cell activation and tumor inhibition, and a phase 1 first-in-human trial ongoing for advanced solid tumors.[3][5][6][7]

Targets

CTLA-4 (Cytotoxic t-lymphocyte–associated protein 4)PDCD1 (Programmed cell death protein 1 receptor)VEGFA (Vascular endothelial growth factor A)

Beyond the preview

Go deeper on CT111.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CT111.